Clinically, reversible and irreversible MAO-A, MAO-B and MAO-A/B inhibitors are prescribed for the management of depression, anxiety disorders, Parkinson’s and Alzheimer’s diseases (Youdim et al., 2006; Bortolato et al., 2008; Tipton, 2018). Here, MAOA is linked to early-onset autosomal dominant Alzheimer disease.